Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces the successful completion of the Placing (as defined below) which was announced earlier today.
A total of 66,666,667 new ordinary shares of one pence each in the capital of the Company (the “Placing Shares”) have been conditionally placed by Peel Hunt LLP (“Peel Hunt”) and Northland Capital Partners Limited (“Northland”) with new and existing investors at a price of 30 pence per Placing Share (the “Placing Price”) to raise a total of £20.0 million (US$25.8 million) for the Company (before expenses) (the “Placing”). The Placing Shares will represent 34.0 per cent. of the issued ordinary share capital of the Company prior to the Placing. The Placing Price represents a discount of 11.7 per cent. to the trailing ten day VWAP of 34.0 pence and a discount of 21.1 per cent to the Company’s mid-market closing price as at 1 June 2017.
The Placing remains conditional, inter alia, on the passing of certain resolutions by shareholders of the Company at a General Meeting to be convened on 22 June 2017. A circular convening the General Meeting will be posted to shareholders on Monday 5 June 2017, and will also be available on the Company’s website, www.motifbio.com.
Application will be made to the London Stock Exchange for the admission of the Placing Shares to trading on AIM. Subject to the passing of the resolutions at the General Meeting to be convened on 22 June 2017, Admission of the Placing Shares is expected to occur at 8.00 a.m. on 23 June 2017 or such other date as the Company and Peel Hunt may agree (being not later than 8.00 a.m. on 7 July 2017). The Placing Shares will, following Admission, rank in full for all dividends and distributions declared, made or paid in respect of the issued ordinary share capital of the Company and otherwise rank pari passu in all other respects with the existing ordinary shares in the capital of the Company.
Total Voting Rights
Following the issue of the Placing Shares, the Company’s issued share capital will comprise 262,878,775 ordinary shares of one pence each. The total number of voting rights in the Company will be 262,878,775. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.
Graham Lumsden, CEO of Motif Bio, commented: “This financing has been well received and gives us the resources to complete the REVIVE-2 Phase 3 clinical trial and file a New Drug Application and Marketing Authorisation Application in the first half of 2018 to achieve marketing approval of iclaprim in the US and Europe. I am delighted by the support shown by our existing shareholders and also welcome a number of new institutional holders to the register.”
Related Party Transaction
The subscription for Placing Shares by Invesco Asset Management Limited (“IAML”) constitutes a related party transaction in accordance with Rule 13 of the AIM Rules for Companies by virtue of IAML being a substantial shareholder in the Company. The Directors consider, having consulted with Peel Hunt, the Company’s nominated adviser, that the terms of the transaction are fair and reasonable in so far as the Company’s Shareholders are concerned. IAML has committed to an investment of 16,789,994 Placing Shares at the Placing Price.
This announcement contains inside information. The person responsible for arranging for the release of this announcement on behalf of the Company is Rob Dickey, CFO.
A copy of this announcement has been posted on the Company’s website at www.motifbio.com
All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned